BridgeBio reported that encaleret met primary and key secondary endpoints in a global Phase III study for autosomal dominant hypocalcemia type 1 (ADH1), with 76% of treated patients achieving target serum and urine calcium control at 24 weeks versus 4% on conventional therapy. The company also announced positive topline results earlier for BBP‑418 in a limb‑girdle muscular dystrophy cohort, marking consecutive late‑stage wins and strengthening a regulatory filing pathway for encaleret next year. ADH1 is a genetic hypoparathyroidism driven by activating CaSR mutations; encaleret's data normalized parathyroid hormone and reduced supplement dependence in responders.